Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells

Cancer Research

Volumn 63, Issue 10, 2003, Pages 2416-2424

  Evangelou, Andreas ^a,b,d   Letarte, Michelle ^a,d,e   Jurisica, Igor ^c,d,e   Sultan, Mujahid ^c   Murphy, Kathleen J ^c   Rosen, Barry ^c   Brown, Theodore J ^b,d,f  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; BRCA1 PROTEIN; BRCA2 PROTEIN; COMPLEMENTARY DNA; MESSENGER RNA; RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CANCER CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; HORMONAL REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CANCER; OVARY DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTIVIN RECEPTORS, TYPE I; ANDROGENS; CELL DIVISION; DIHYDROTESTOSTERONE; EPITHELIAL CELLS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HISTONE ACETYLTRANSFERASES; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; OVARY; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 0037843633     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics, 2001. CA Cancer J. Clin., 51: 15-36, 2001.
2. National Cancer Institute of Canada. Canadian Cancer Statistics 2001. Toronto, Ontario: National Cancer Institute of Canada, 2001.
3. Modugno, F., Ness, R. B., and Wheeler, J. E. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann. Epidemiol., 11: 568-574, 2001.
4. Whittemore, A. S., Gong, G., and Itnyre. J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U. S. population-based case-control studies of ovarian cancer. Am. J. Hum. Genet., 60: 496-504, 1997.
5. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J. Nat. Cancer Inst., 91: 1310-1316, 1999.
6. Risch, H. A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Nat. Cancer Inst., 90: 1774-1786, 1998.
7. Schildkraut, J. M., Schwingl, P. J., Bastos, E., Evanoff, A., and Hughes, C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet. Gynecol., 88: 554-559, 1996.
8. Helzlsouer, K. J., Alberg, A. J., Gordon, J. B., Longcope, C., Bush, T. L., Hoffman, S. C., and Cornstock, G. W. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA, 274: 1926-1930, 1995.
9. Chadha, S., Rao, B. R., Slotman, B. J., van Vroonhoven, C. C. J., and van der Kwast, T. H. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum. Pathol. 24: 90-95, 1993.
10. Kühnel, R., De Graaff, J., Rao, B. R., and Stolk, J. G. Androgen receptor predominance in human ovarian cancer. J. Steroid Biochem. 26: 393-397, 1987.
11. Lau, K-M., Mok, S. C., and Ho, S-M. Expression of human estrogen receptor-α and-β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc. Natl. Acad. Sci. USA, 96: 5722-5727, 1999.
12. Edmondson, R. J., Monaghan, J. M., and Davies, B. R. The human ovarian surface epithelium is an androgen responsive tissue. Br. J. Cancer, 86: 879-885, 2002.
13. Shibata, H., Spencer, T. E., Onate, S. A., Jenster, G., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog. Horm. Res., 52: 141-164, 1997.
14. Jenster, G. Coactivators and coreceptors as mediators of nuclear receptor function: an update. Mol. Cell. Endocrinol., 143: 1-7, 1998.
15. Spencer, T. E., Jenster, G., Burcin, M. M., Allis, C. D., Zhou, J., Mizzen, C. A., McKenna, N. J., Onate, S. A., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (Lond.), 389: 194-198, 1997.
16. Kim, M. Y., Hsiao, S. J., and Kraus, W. L. A role for coactivators and histone acetylation in estrogen receptor α-mediated transcription initiation. EMBO J., 20: 6084-6094, 2001.
17. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X-Y., Sauter, G., Kallioniemi, O-P., Trent, J. M., and Meltzer, P. S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (Wash. DC), 277: 965-968, 1997.
18. Tanner, M. M., Grenman, S., Koul, A., Johannsson, O., Meltzer, P., Pejovic, T., Borg, Å., and Isola, J. J. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin. Cancer Res. 6: 1833-1839, 2000.
19. Shaw, P. A., Rittenberg, P. V. C., and Brown, T. J. Activation of ARA70 mRNA expression in ovarian cancer. Gynecol. Oncol., 80: 132-138, 2001.
20. Chamberlain, N. L., Driver, E. D., and Miesfeld, R. L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res., 22: 3181-3186, 1994.
21. Levine, D. A., and Boyd, J. A. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res., 61: 908-911, 2001.
22. Berchuck, A., Rodriguez, G., Olt, G., Whitaker, R., Boente, M. P., Arrick, B. A., Clarke-Pearson, D. L., and Bast, R. C. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β. Am. J. Obstet. Gynecol., 166: 676-684, 1992.
23. Havrilesky, L. J., Hurteau, J. A., Whitaker, R. S., Elbendary, A., Wu, S., Rodriguez, G. C., Bast, R. C., and Berchuck, A. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor β. Cancer Res., 55: 944-948, 1995.
24. Hurteau, J., Rodriguez, G. C., Whitaker, R. S., Shah, S., Mills, G., Bast, R. C., and Berchuck, A. Transforming growth factor-β inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer (Phila.), 74: 93-99, 1994.
25. Pasche, B., Kolachana, P., Nafa, K., Satagopan, J., Chen, Y-G., Lo, R. S., Brener, D., Yang, D., Kirstein, L., Oddoux, C., Ostrer, H., Vineis, P., Varesco, L., Jhanwar, S., Luzzatto, L., Massagué, J., and Offit. K. TβR-I (6A) is a candidate tumor susceptibility allele. Cancer Res., 59: 5678-5682, 1999.
26. Wang, J., Sun, L., Myeroff, L., Wang, X., Gentry, L. E., Yang, J., Liang, J., Zborowska, E., Markowitz, S., Wilson, J. K., and Brattain, M. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J. Biol. Chem. 270: 22044-22049, 1995.
27. Abe, T., Ouyang, H., Migata, T., Kato, Y., Kimura, M., Shiiba, K., Sunamura, M., Matsuno, S., and Horii, A. The somatic mutation frequency of the transforming growth factor β receptor type II gene varies widely among different cancers with microsatellite instability. Eur. J. Surg. Oncol., 22: 474-477, 1996.
28. Evangelou, A., Jindal, S. K., Brown, T. J., and Letarte, M. Down-regulation of TGF-β receptors by androgen in ovarian cancer cells. Cancer Res., 60: 929-935, 2000.
29. Hirte, H. W., Clark, D. A., Mazurka, J., O'Connell, G., and Rusthoven J. A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma. Gynecol. Oncol., 44: 223-226, 1992.
30. Quackenbush, E. J., and Letarte, M. Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies. J. Immunol., 134: 1276-1285, 1985.
31. Linsley, P. S., Brown, J. P., Magnani, J. L., and Horn, D. Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients. Cancer Res., 48: 2138-2148, 1988.
32. Marks, A. Sutherland, D. R., Bailey, D., Iglesias, J., Law, J., Lei, M., Yeger, H., Banerjee, D., and Baumal, R. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br. J. Cancer, 80: 569-578, 1999.
33. Letarte, M., Iturbe, S., and Quackenbush, E. J. A glycoprotein of molecular weight 85, 000 on human cells of B-lineage: detection with a family of monoclonal antibodies. Mol. Immunol., 22: 113-124, 1985.
34. Murphy, L. D., Herzog, C. E., Rudick, J. B., Fojo, A. T., and Bates, S. E. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry, 29: 10351-10356, 1990.
35. Jindal, S. K., Ishii, E., Letarte, M., Vera, S., Teerds, K. J., and Dorrington, J. H. Regulation of transforming growth factor a gene expression in an ovarian surface epithelial cell line derived from a human carcinoma. Biol. Reprod., 52: 1027-1037, 1995.
36. Sultan, M., Wigle, D., Cumbaa, C. A., Maziarz, M., Glasgow, J., Tsao, M. S., and Jurisica, I. Binary tree-structured vector quantization approach to clustering and visualizing microarray data. Bioinformatics, 18(Suppl. 1): S111-S119, 2002.
37. Linsley, P. S., Ochs, V., Horn, D., Ring, D. B., and Frankel, A. E. Heritable variation in expression of multiple tumor associated epitopes on a high molecular weight mucin-like antigen. Cancer Res., 46: 6380-6386, 1986.
38. Auersperg, N., Maines-Bandiera, S., Booth, J. H., Lynch, H. T., Godwin, A. K., and Hamilton, T. C. Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. Am. J. Obstet. Gynecol., 173: 558-565, 1995.
39. Auersperg, N., Maines-Bandiera, S. L., Dyck, H. G., and Kruk, P. A. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Investig., 71: 510-518, 1994.
40. Strobel, T., and Cannistra, S. A. β1-Integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol. Oncol., 73: 362-367, 1999.
41. Casey, R. C., and Skubitz, A. P. CD44 and β1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clin. Exp. Metastasis, 18: 67-75, 2000.
42. Haning, R. V., Jr., Flood, C. A., Hackett, R. J., Loughlin, J. S., McClure, N., and Longcope, C. Metabolic clearance rate of dehydroepiandrosterone sulfate, its metabolism to testosterone, and its intrafollicular metabolism to dehydroepiandrosterone, androstenedione, testosterone, and dihydrotestosterone in vivo. J. Clin. Endocrinol. Metab., 72: 1088-1095, 1991.
43. Morgan, P. M., Boatman, D. E, and Bavister, B. D. Relationships between follicular fluid steroid hormone concentrations, oocyte maturity, in vitro fertilization and embryonic development in the rhesus monkey. Mol. Reprod. Dev., 27: 145-151, 1990.
44. Scully, R. E. Pathology of ovarian cancer precursors. J. Cell. Biochem., 23(Suppl.): 208-218, 1995.
45. Feeley, K. M., and Wells, M. Precursor lesions of ovarian epithelial malignancy. Histopathology, 38: 87-95, 2001.
46. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massagué, J. Mechanism of activation of the TGF-β receptor. Nature (Lond.), 370: 342-347, 1994.
47. Mulder, K. M. Role of Ras and Mapks in TGFβ signaling. Cytokine Growth Factor Rev., 11: 23-35, 2000.
48. Karlan, B. Y., Jones, J., Greenwald, M., and Lagasse, L. D. Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am. J. Obstet. Gynecol., 173: 97-104, 1995.
49. Syed, V., Ulinski, G., Mok, S. C., Yiu, G. K., and Ho, S. M. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res., 61: 6768-6776, 2001.
50. Tekur, S., Lau, K. M., Long, J., Burnstein, K., and Ho, S. M. Expression of RFG/ELE1α/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids. Mol. Carcinog., 30: 1-13, 2001.
51. Quandt, K., Frech, K., Karas, H., Wingender, E., and Werner, T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res., 23: 4878-4884, 1995.
52. Venkitaraman, A. R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108: 171-182, 2002.
53. Monteiro, A. N. BRCA1: exploring the links to transcription. Trends Biochem. Sci., 25: 469-474, 2000.
54. Thompson, M. E., Jensen, R. A., Obermiller, P. S., Page, D. L., and Holt, J. T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet., 9: 444-450, 1995.
55. Holt, J. T., Thompson, M. E., Szabo, C., Robinson-Benion, C., Arteaga, C. L., King, M. C., King, M. C., and Jensen. R. A. Growth retardation and turnout inhibition by BRCA1. Nat. Genet., 12: 298-302, 1996.
56. Fan, S., Wang, J-A., Yuan, R., Ma, Y., Meng, Q., Erdos, M. R., Pestell, R. G., Yuan, F., Auborn, K. J., Goldberg, I. D., and Rosen, E. M. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science (Wash. DC), 284: 1354-1356, 1999.
57. Fan, S., Ma, Y. X., Wang, C., Yuan, R. Q., Meng, Q., Wang, J. A., Erdos, M., Goldberg, I. D., Webb, P., Kushner, P. J., Pestell, R. G., and Rosen, E. M. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene, 20: 77-87, 2001.
58. Park, J. J., Irvine, R. A., Buchanan, G., Koh, S. S., Park, J. M., Tilley, W. D., Stallcup, M. R., Press, M. F., and Coetzee, G. A. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res., 60: 5946-5949, 2000.
59. Yeh, S., Hu, Y. C., Rahman, M., Lin, H. K., Hsu, C. L., Ting, H. J., Kang, H. Y., and Chang, C. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc. Natl. Acad. Sci. USA, 97: 11256-11261, 2000.
60. Thompson, D., and Easton, D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet., 68: 410-419, 2001.
61. Alen, P., Claessens, F., Schoenmakers, E., Swinnen, J. V., Verhoeven, G., Rombauts, W., and Peeters, B. Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1α with multiple steroid receptors and identification of an internally deleted ELE1β isoform. Mol. Endo., 13: 117-128, 1999.
62. Yeh, S., Miyamoto, H., Shima, H., and Chang, C. From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc. Natl. Acad. Sci. USA, 95: 5527-5532, 1998.
63. Suen, C. S., Berrodin, T. J., Mastroeni, R., Cheskis, B. J., Lyttle, C. R., and Frail, D. E. A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J. Biol. Chem., 273: 27645-27653, 1998.
64. Bevan, C. L., Hoare, S., Claessens, F., Heery, D. M., and Parker, M. G. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC-1. Mol. Cell. Biol., 19: 8383-8392, 1999.
65. Choi, K-C., Kang, S. K., Tai, C-J., Auersperg, N., and Leung, P. C. K. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology, 142: 2351-2360, 2001.
66. Akahira, J., Inoue, T., Suzuki, T., Ito, K., Konno, R., Sato, S., Moriya, T., Okamura, K., Yajima, A., and Sasano, H. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br. J. Cancer, 83: 1488-1494, 2000.
67. Bu, S-Z., Yin, D-L., Ren, X-H., Jiang, L-Z., Wu, Z-J., Gao, Q-R., and Pei, G. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer (Phila.), 79: 1944-1950, 1997.